| Ana C Domingues, MD | |
|
The Cambridge Hospital, 1493 Cambridge Street, Cambridge, MA 02139 | |
| (617) 665-1660 | |
| Not Available |
| Full Name | Ana C Domingues |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | The Cambridge Hospital, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356490908 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 219923 (Massachusetts) | Primary |
| Entity Name | Atrius Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871639914 PECOS PAC ID: 4789588641 Enrollment ID: O20031121000582 |
News Archive
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing ten new Collaborative Research Centers (CRCs) to further support top-level research in Germany.
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become "addicted" to glucose could open up fresh approaches to therapy strategies for cancers with high levels of an amino acid transporter called solute carrier family 7 member 11 (SLC7A11).
Today the GridTalk project launches its 8th GridBriefing at the Enabling Grids for E-sciencE (EGEE) conference in Barcelona. The report covers how information and communication technologies (ICTs), particularly computing grids, are used in the health and biomedical sectors of European research. EGEE has supported this research community since the project's birth and it is the second largest user group after physics research.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).
› Verified 4 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518908136 PECOS PAC ID: 4486567104 Enrollment ID: O20031204000710 |
News Archive
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing ten new Collaborative Research Centers (CRCs) to further support top-level research in Germany.
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become "addicted" to glucose could open up fresh approaches to therapy strategies for cancers with high levels of an amino acid transporter called solute carrier family 7 member 11 (SLC7A11).
Today the GridTalk project launches its 8th GridBriefing at the Enabling Grids for E-sciencE (EGEE) conference in Barcelona. The report covers how information and communication technologies (ICTs), particularly computing grids, are used in the health and biomedical sectors of European research. EGEE has supported this research community since the project's birth and it is the second largest user group after physics research.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).
› Verified 4 days ago
| Entity Name | Beth Israel Deaconess Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548202641 PECOS PAC ID: 8123936119 Enrollment ID: O20041001000827 |
News Archive
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing ten new Collaborative Research Centers (CRCs) to further support top-level research in Germany.
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become "addicted" to glucose could open up fresh approaches to therapy strategies for cancers with high levels of an amino acid transporter called solute carrier family 7 member 11 (SLC7A11).
Today the GridTalk project launches its 8th GridBriefing at the Enabling Grids for E-sciencE (EGEE) conference in Barcelona. The report covers how information and communication technologies (ICTs), particularly computing grids, are used in the health and biomedical sectors of European research. EGEE has supported this research community since the project's birth and it is the second largest user group after physics research.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ana C Domingues, MD 260 Cochituate Rd, Framingham, MA 01701-4608 Ph: (508) 532-7510 | Ana C Domingues, MD The Cambridge Hospital, 1493 Cambridge Street, Cambridge, MA 02139 Ph: (617) 665-1660 |
News Archive
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing ten new Collaborative Research Centers (CRCs) to further support top-level research in Germany.
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become "addicted" to glucose could open up fresh approaches to therapy strategies for cancers with high levels of an amino acid transporter called solute carrier family 7 member 11 (SLC7A11).
Today the GridTalk project launches its 8th GridBriefing at the Enabling Grids for E-sciencE (EGEE) conference in Barcelona. The report covers how information and communication technologies (ICTs), particularly computing grids, are used in the health and biomedical sectors of European research. EGEE has supported this research community since the project's birth and it is the second largest user group after physics research.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).
› Verified 4 days ago
Kathleen Forest Harney, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1600 | |
Dr. Arielle Caplin, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1000 | |
Latoya Shari Jackson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-498-1660 | |
Dr. Eman Elkadry, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 725 Concord Ave, Ste 3300, Cambridge, MA 02138 Phone: 617-354-5452 Fax: 617-497-7503 | |
Alexander Bruscke, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 725 Concord Ave Ste 3500, Cambridge, MA 02138 Phone: 617-354-5452 | |
Arthur G Spector, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-2800 | |
Dr. Jessica Leigh Verosko, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cha - Ob/gyn - Cambridge Campus, Cambridge, MA 02139 Phone: 617-498-1660 |